Physician profile
Joseph Jensen
NPI 1740281500
$4,428.07
in general payments reported to CMS, 2019-2025
29 companies · $564 in 2025
The $564 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $604 · 2020: $562 · 2021: $651 · 2022: $665 · 2023: $713 · 2024: $669 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $679.10 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Pfizer INC. | $492.75 | 2019-2025 | |
| Galderma Laboratories, L.P. | $447.28 | 2019-2025 | Aklief, Nemluvio |
| Ucb, INC. | $411.55 | 2021-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $348.87 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $331.47 | 2019-2025 | Cabtreo, Jublia |
| Novartis Pharmaceuticals Corporation | $204.30 | 2019-2025 | |
| Astellas Pharma US INC | $186.10 | 2019-2020 | |
| Janssen Biotech, INC. | $168.94 | 2022-2025 | Simponi, Stelara, Simponi Aria |
| Genzyme Corporation | $142.32 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $125.51 | 2022-2024 | Nuzyra |
| Amgen INC. | $110.25 | 2022-2024 | Otezla |
| Lilly USA, LLC | $107.29 | 2020-2024 | Ebglyss |
| Dermavant Sciences, INC. | $99.66 | 2023-2024 | Vtama |
| Organon LLC | $79.79 | 2025 | Vtama |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $67.21 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $59.41 | 2021-2024 | Dupixent |
| Epi Health, LLC | $54.62 | 2019 | |
| Dermira, INC. | $52.99 | 2019-2021 | |
| Leo Pharma INC. | $47.60 | 2022-2023 | Adbry |
| Allergan, INC. | $37.86 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.11 | 2019 | |
| Arcutis Biotherapeutics, INC. | $32.67 | 2023 | |
| Incyte Corporation | $28.38 | 2022 | |
| Biofrontera INC. | $17.64 | 2020 | |
| Shire North American Group INC | $17.27 | 2019 | |
| Botanix Sb INC | $16.79 | 2025 | Sofdra |
| Mylan Pharmaceuticals INC. | $12.69 | 2019 | |
| Qiagen, LLC | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Jensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.